Breast Cancer Research
Whether you have early stage breast cancer or metastatic breast cancer, research can play an important role in your treatment plan, offering you access to leading-edge treatments. It can also play an important role in other peoples’ lives. By participating in a breast cancer clinical trial, you help pave the way to new prevention, detection and treatment strategies that can offer hope to people with cancer.
As an academic medical center, we are involved in some of the most groundbreaking cancer trials available today. By choosing the USC Breast Center for your breast care, you have access to clinical trials that are helping make breast cancer a disease of the past.
- Breast cancer breakthroughs
- Breast cancer clinical trials
- Finding a cure
- Improving detection, treatment, prevention
- National Cancer Institute (NCI) designation
- Understanding breast cancer causes
What our National Cancer Institute designation means
In 1973, USC Norris Comprehensive Cancer Center was designated as one of the country’s original eight comprehensive cancer centers by the National Cancer Institute (NCI), the federal government’s principle agency for cancer research and training. As an NCI-designated cancer center, we anchor the country’s cancer research efforts, making scientific discoveries that are translated into new treatments for people with cancer. The collective work of NCI researchers has led to important medical advances that have increased the number of cancer survivors in the United States and worldwide.
USC Norris cancer research breakthroughs
Our clinician-scientists have been at the forefront of cancer research for more than 40 years, making historic breakthroughs that have changed the way we understand breast cancer and how it’s treated.
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
I-SPY will compare the efficacy of novel drugs in combination with standard chemotherapy with the efficacy of standard therapy alone. The goal is identify improved treatment regimens for subsets ...Learn More ≫
Light-Scattering Spectroscopy for the Detection of Stage II-III Breast Cancer: A Pilot Study
PRIMARY OBJECTIVES: I. To evaluate whether light-scattering spectroscopy can reliably distinguish between two subject groups: those with clinical stage II or stage III breast cancer and those without breast ...Learn More ≫
Prone Partial Breast Irradiation (PBI): Prospective Randomized Controlled Non-inferiority Trial to Compare Radiation Fibrosis With Five Versus Three Fractions
Partial breast irradiation (PBI) is becoming a new paradigm for breast cancer radiation. No type I or II evidence is currently available to demonstrate equivalence to standard whole breast radiotherapy, ...Learn More ≫
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
PRIMARY OBJECTIVES: I. To evaluate whether the reconstruction complication rate at 24 months post radiation is non-inferior with hypofractionation. SECONDARY OBJECTIVES: I. To evaluate the incidence of acute and ...Learn More ≫